Literature DB >> 12941272

Cyclin E ablation in the mouse.

Yan Geng1, Qunyan Yu, Ewa Sicinska, Manjusri Das, Jürgen E Schneider, Shoumo Bhattacharya, William M Rideout, Roderick T Bronson, Humphrey Gardner, Piotr Sicinski.   

Abstract

E type cyclins (E1 and E2) are believed to drive cell entry into the S phase. It is widely assumed that the two E type cyclins are critically required for proliferation of all cell types. Here, we demonstrate that E type cyclins are largely dispensable for mouse development. However, endoreplication of trophoblast giant cells and megakaryocytes is severely impaired in the absence of cyclin E. Cyclin E-deficient cells proliferate actively under conditions of continuous cell cycling but are unable to reenter the cell cycle from the quiescent G(0) state. Molecular analyses revealed that cells lacking cyclin E fail to normally incorporate MCM proteins into DNA replication origins during G(0)-->S progression. We also found that cyclin E-deficient cells are relatively resistant to oncogenic transformation. These findings define a molecular function for E type cyclins in cell cycle reentry and reveal a differential requirement for cyclin E in normal versus oncogenic proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941272     DOI: 10.1016/s0092-8674(03)00645-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  256 in total

1.  RB reversibly inhibits DNA replication via two temporally distinct mechanisms.

Authors:  Steven P Angus; Christopher N Mayhew; David A Solomon; Wesley A Braden; Michael P Markey; Yukiko Okuno; M Cristina Cardoso; David M Gilbert; Erik S Knudsen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

2.  An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry.

Authors:  Peter M Burch; Ziqiang Yuan; Anne Loonen; Nicholas H Heintz
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 3.  Regulation of DNA replication during development.

Authors:  Jared Nordman; Terry L Orr-Weaver
Journal:  Development       Date:  2012-02       Impact factor: 6.868

Review 4.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

Review 5.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Andrew Burgess; Andrew J Deans; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

7.  Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

8.  Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.

Authors:  Tiziana Parisi; Andreas R Beck; Nathalie Rougier; Tom McNeil; Linda Lucian; Zena Werb; Bruno Amati
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

9.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.

Authors:  Haksier Ehedego; Antje Mohs; Bettina Jansen; Kanishka Hiththetiya; Piotr Sicinski; Christian Liedtke; Christian Trautwein
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.